Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTXNASDAQ:BLPHNASDAQ:ENVBNASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10$0.08$0.01▼$0.72N/A1.271.32 million shs231,126 shsBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shs7,027 shsENVBEnveric Biosciences$1.20-5.5%$1.30$1.01▼$11.99$2.97M0.68760,660 shs1.41 million shsPRFXPainReform$1.95+2.6%$2.11$1.68▼$19.20$3.93M0.691.43 million shs44,027 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%0.00%BLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%-79.70%ENVBEnveric Biosciences-5.51%-2.83%-11.11%-43.40%-89.87%PRFXPainReform+2.63%+4.28%-15.95%-37.10%-29.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences2.9651 of 5 stars3.54.00.00.03.50.01.3PRFXPainReform1.8008 of 5 stars3.02.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyx 0.00N/AN/AN/ABLPHBellerophon Therapeutics 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00733.33% UpsidePRFXPainReform 2.00Hold$8.00310.26% UpsideCurrent Analyst Ratings BreakdownLatest APTX, ENVB, PRFX, and BLPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025ENVBEnveric BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ABLPHBellerophon Therapeutics$5.64M0.03N/AN/A$0.27 per share0.04ENVBEnveric BiosciencesN/AN/AN/AN/A$10.71 per shareN/APRFXPainReformN/AN/AN/AN/A$111.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/ABLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/AN/AN/AN/AENVBEnveric Biosciences-$17.29M-$38.38N/AN/AN/AN/A-221.54%-164.32%8/11/2025 (Estimated)PRFXPainReform-$9.34M-$147.33N/A∞N/AN/A-450.64%-241.33%8/13/2025 (Estimated)Latest APTX, ENVB, PRFX, and BLPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AENVBEnveric BiosciencesN/A5.175.17PRFXPainReformN/A0.61N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/ABLPHBellerophon Therapeutics10.61%ENVBEnveric Biosciences13.82%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%BLPHBellerophon Therapeutics5.20%ENVBEnveric Biosciences1.10%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableBLPHBellerophon Therapeutics2012.23 million11.60 millionNo DataENVBEnveric Biosciences202.47 million656,000Not OptionablePRFXPainReform42.01 million95,000Not OptionableAPTX, ENVB, PRFX, and BLPH HeadlinesRecent News About These CompaniesBlade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software SalesMay 27 at 12:12 PM | prnewswire.comPainReform Ltd.May 12, 2025 | barrons.comPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar ProjectsMay 7, 2025 | finance.yahoo.comPainReform Ltd. Launches Strategic Pilot Program with Econergy Renewable Energy Ltd. to Optimize Solar Energy Production using DeepSolar™ PlatformMay 7, 2025 | quiverquant.comPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar ProjectsMay 7, 2025 | globenewswire.comPainReform Regains Nasdaq Compliance as of April 16, 2025April 17, 2025 | tipranks.comPainReform announces expansion into SEM sectorApril 10, 2025 | markets.businessinsider.comPainReform Shareholders Approve Key Proposals at April MeetingApril 10, 2025 | tipranks.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | finance.yahoo.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Ltd: PainReform Provides Year-End Business UpdateApril 8, 2025 | finanznachrichten.dePainReform says shareholder equity now exceeds required thresholdApril 8, 2025 | markets.businessinsider.comPainReform Expands into Clean Energy with DeepSolar AcquisitionApril 7, 2025 | tipranks.comPainReform Provides Year-End Business UpdateApril 7, 2025 | globenewswire.comPainReform’s Shareholder Meeting Adjourned Due to Lack of QuorumApril 3, 2025 | tipranks.comPainReform acquires AI solar analytics firm DeepSolarMarch 7, 2025 | uk.investing.comPainReform Ltd: PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar AnalyticsMarch 5, 2025 | finanznachrichten.dePainReform completes acquisition of DeepSolarMarch 5, 2025 | markets.businessinsider.comPainReform Ltd. Completes Acquisition of DeepSolar, Expanding into Clean Energy SectorMarch 5, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPTX, ENVB, PRFX, and BLPH Company DescriptionsAptinyx NASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Bellerophon Therapeutics NASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Enveric Biosciences NASDAQ:ENVB$1.20 -0.07 (-5.51%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.25%) As of 05/28/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.PainReform NASDAQ:PRFX$1.95 +0.05 (+2.63%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$1.92 -0.03 (-1.33%) As of 05/28/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
